Scilex shares jumped 10% after iHolding proposed a $100M stock deal.
iHolding plans to buy SCLX shares at $15 each under the term sheet.
The funding could support Scilex’s growth, products, and partnerships.
The deal still needs due diligence, approvals, and final agreements.
Scilex framed the deal as support for its non-opioid pain platform.
Scilex Holding Company (SCLX) shares rose sharply after the company announced a proposed $100 million common stock investment from iHolding Group LLP. SCLX gained 10.00% to $8.59 after briefly moving above $10 in early trading. The stock later pulled back, yet it recovered steadily and traded near session highs by late morning.
Scilex said it signed a binding term sheet with iHolding Group LLP, a private investment group based in Almaty, Kazakhstan. The agreement outlines a planned purchase of newly issued Scilex common shares. The proposed investment would total $100 million, subject to further approvals and final agreements.
The company expects iHolding to buy shares at $15.00 each. That price would represent about 6.67 million new shares. The proposed deal values the stock above its late-morning trading level.
The announcement gave SCLX fresh momentum during the session. Shares spiked early, then gave back part of the move. However, the stock regained strength as traders reacted to the financing plan.
Scilex plans to use the proposed investment to support its strategic growth. The company listed product development, commercialization, acquisitions, and partnerships among its expected uses. It also plans to support working capital, operations, intellectual property and broader corporate needs.
Scilex operates in non-opioid pain management and related healthcare markets. The company focuses on products for acute pain, chronic pain, neurodegenerative disease, and cardiometabolic disease. As a result, the proposed funding could support both commercial operations and pipeline work.
The deal still requires several steps before completion. The parties must finish due diligence and negotiate definitive agreements. They also need board approvals, stockholder approval, and any required regulatory clearances.
iHolding described the proposed Scilex investment as part of a wider healthcare and biotechnology strategy. The group focuses on healthcare, technology, and cross-border strategic investments. It operates as a private investment vehicle in the Medeu District of Almaty.
The proposed deal also fits Kazakhstan’s growing interest in healthcare and biotechnology development. iHolding aims to support pharmaceutical manufacturing, research, biotechnology innovation, and international healthcare distribution. Therefore, the Scilex transaction could connect U.S. biotech activity with Central Asian healthcare ambitions.
Scilex framed the proposed investment as a strategic growth opportunity. The company also noted that the transaction remains conditional and incomplete. Still, the announcement lifted SCLX stock as the market reacted to the size and proposed pricing of the deal.
The post Scilex Holding Company (SCLX) Stock: Shares Jump as iHolding Eyes $100M Deal appeared first on CoinCentral.
